Expression of CMTM6 in breast cancer tissues and its correlation with patients’ clinicopathological characteristics and prognosis
10.3872/j.issn.1007-385x.2020.04.008
- VernacularTitle:趋化素样因子超家族6在乳腺癌组织中的表达及其与临床病理特征和预后的关系
- Author:
YANG Xiaojun
1
,
2
,
3
;
WEI Li
1
,
2
,
3
;
ZHENG Xiao
1
,
2
,
3
;
XU Bin
1
,
2
,
3
;
WANG Qi
1
,
2
,
3
;
LIU Yingting
1
,
2
,
3
;
ZHANG Dachuan
4
;
JIANG Jingting
1
,
2
,
3
Author Information
1. a. Department of Tumor Biological Treatment &
2. Research Center of Tumor Immunotherapy Engineering Technology in Jiangsu Province &
3. Institute of Cell Therapy, Soochow University
4. b. Department of Pathology, the Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu, China
- Publication Type:Journal Article
- Keywords:
breast cancer;
chemokine-like factor-like MARVEL transmembrane domain-containing family member 6 (CMTM6);
tissue chip;
prognosis
- From:
Chinese Journal of Cancer Biotherapy
2020;27(4):391-395
- CountryChina
- Language:Chinese
-
Abstract:
[Abstract] Objective: To investigate the expression of chemokine-like factor-like MARVEL transmembrane domain-containing family member 6 (CMTM6) in breast cancer tissues and its correlation with clinicopathological features and prognosis of patients. Methods:Atotal of 136 breast cancer tissue chips (purchased from Superchip Company), including 42 pairs of matched cancer and paracancerous tissues, were used for this study. The expression level of CMTM6 in cancer and paracancerous tissues was detected by immunohistochemistry. The comparison of CMTM6 expression between breast cancer and paracancerous tissues was conducted by paired χ2 test. The relationship between CMTM6 expression in breast cancer tissues and the clinicopathological characteristics of patients was analyzed by χ2 test. Kaplan-Meier and Log rank test analyses were used to analyze the relationship between CMTM6 expression and the survival of patients, and Cox model was used to evaluate the effect of different indicators on the prognosis of patients. Results: The expression of CMTM6 in breast cancer tissues was significantly higher than that in paracancerous tissues (P<0.01). The expression of CMTM6 was correlated with pathological type of breast cancer and HER2 positivity (P<0.05). The survival time of patients in CMTM6 high expression group was significantly shorter than that of patients in CMTM6 low expression group (P<0.05). Pathological type (HR=10.374, 95%CI: 3.529-30.497, P<0.01), TNM stage (HR=4.599, 95%CI: 1.784-11.856, P<0.01), triple-negative breast cancer (HR=3.370, 95%CI: 1.055-10.761, P<0.05) and high expression of CMTM6 (HR=0.195, 95%CI: 0.073-0.518, P<0.01) were independent risk factors for prognosis of breast cancer patients. Conclusion: CMTM6 is highly expressed in breast cancer tissues, which can be used as a risk factor for prognosis evaluation of breast cancer patients.
- Full text:20200408.pdf
